Literature DB >> 11849266

Cost of nonmelanoma skin cancer treatment in the United States.

J G Chen1, A B Fleischer, E D Smith, C Kancler, N D Goldman, P M Williford, S R Feldman.   

Abstract

BACKGROUND: Despite being the most prevalent form of cancer, the economic impact of nonmelanoma skin cancer (NMSC) in the United States has not been assessed.
OBJECTIVE: To determine the overall cost and to estimate the cost per episode of NMSC care in the United States in physicians' offices, outpatient surgery centers, and inpatient settings.
METHODS: Data from the Medicare Current Beneficiary Study 1992-1995 were analyzed to obtain the total cost of NMSC and the cost in different settings. To normalize these data on a per episode basis, the cost in each setting was divided by the number of procedures performed in each setting obtained from the National Hospital Discharge Survey (NHDS, 1992-1997), the National Survey of Ambulatory Surgery (NSAS, 1994-1996), and the National Ambulatory Medical Care Survey (NAMCS, 1995).
RESULTS: The total cost of NMSC care in the United States in the Medicare population is $426 million/year. Physician office-based procedures for NMSC accounted for the greatest percentage of money spent to treat NMSC and the greatest percentage of procedures. The average cost per episode of NMSC when performed in a physician's office setting was found to be $492. The cost per episode of care in inpatient and outpatient settings were $5537 and $1043, respectively.
CONCLUSION: Compared to other cancers, the relative magnitude of NMSC treatment costs is currently small because NMSC is managed efficiently and effectively, primarily in office-based settings. Legislative or regulatory measures that discourage office treatment of NMSC will lead to increased cost.

Entities:  

Mesh:

Year:  2001        PMID: 11849266     DOI: 10.1046/j.1524-4725.2001.01004.x

Source DB:  PubMed          Journal:  Dermatol Surg        ISSN: 1076-0512            Impact factor:   3.398


  35 in total

1.  Viruses in Skin Cancer (VIRUSCAN): Study Design and Baseline Characteristics of a Prospective Clinic-Based Cohort Study.

Authors:  Rossybelle P Amorrortu; Neil A Fenske; Basil S Cherpelis; Laxmi Vijayan; Yayi Zhao; Juliana Balliu; Jane L Messina; Vernon K Sondak; Anna R Giuliano; Tim Waterboer; Michael Pawlita; Tarik Gheit; Massimo Tommasino; Dana E Rollison
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2019-08-19       Impact factor: 4.254

2.  The Nose Knows That Margins Matter.

Authors:  Andrew T Day; Jordan R Salley; Rajiv I Nijhawan
Journal:  Ann Surg Oncol       Date:  2021-03-25       Impact factor: 5.344

3.  Randomized trial of tailored skin cancer prevention for children: the Project SCAPE family study.

Authors:  Karen Glanz; Alana D Steffen; Elinor Schoenfeld; Karyn A Tappe
Journal:  J Health Commun       Date:  2013-06-27

Review 4.  Methodological issues in using multiple years of the Medicare current beneficiary survey.

Authors:  Becky A Briesacher; Jennifer Tjia; Chyke A Doubeni; Yong Chen; Sowmya R Rao
Journal:  Medicare Medicaid Res Rev       Date:  2012-02-08

5.  Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: post hoc analyses of the women's health initiative randomized controlled trial.

Authors:  Jean Y Tang; Teresa Fu; Erin Leblanc; Joann E Manson; David Feldman; Eleni Linos; Mara Z Vitolins; Nathalie C Zeitouni; Joseph Larson; Marcia L Stefanick
Journal:  J Clin Oncol       Date:  2011-06-27       Impact factor: 44.544

Review 6.  Nonmelanoma skin cancer and the risk of second primary cancers: a systematic review.

Authors:  Lee Wheless; Joshua Black; Anthony J Alberg
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2010-06-22       Impact factor: 4.254

Review 7.  Non-Melanoma Skin Cancers in the Older Patient.

Authors:  Ashley Albert; Miriam A Knoll; John A Conti; Ross I S Zbar
Journal:  Curr Oncol Rep       Date:  2019-07-29       Impact factor: 5.075

8.  A randomized, double-blind, placebo-controlled phase 3 skin cancer prevention study of {alpha}-difluoromethylornithine in subjects with previous history of skin cancer.

Authors:  Howard H Bailey; KyungMann Kim; Ajit K Verma; Karen Sielaff; Paul O Larson; Stephen Snow; Theresa Lenaghan; Jaye L Viner; Jeff Douglas; Nancy E Dreckschmidt; Mary Hamielec; Marcy Pomplun; Harry H Sharata; David Puchalsky; Eric R Berg; Thomas C Havighurst; Paul P Carbone
Journal:  Cancer Prev Res (Phila)       Date:  2010-01

9.  A phase III skin cancer chemoprevention study of DFMO: long-term follow-up of skin cancer events and toxicity.

Authors:  Sarah M Kreul; Tom Havighurst; KyungMann Kim; Eneida A Mendonça; Gary S Wood; Stephen Snow; Abbey Borich; Ajit Verma; Howard H Bailey
Journal:  Cancer Prev Res (Phila)       Date:  2012-10-11

10.  Inverse association between serum 25(OH) vitamin D levels and non-melanoma skin cancer in elderly men.

Authors:  Jean Y Tang; Neeta Parimi; Angela Wu; W John Boscardin; James M Shikany; Mary-Margaret Chren; Steven R Cummings; Ervin H Epstein; Douglas C Bauer
Journal:  Cancer Causes Control       Date:  2010-03       Impact factor: 2.506

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.